BioNanomatrix Appoints Gary Zweiger, Ph.D., as Vice President of Business Development.
--Appointment Expands Leadership Team and Strengthens Commercial Focus-- PHILADELPHIA, Dec. 2 /PRNewswire/ -- BioNanomatrix, Inc., a developer of breakthrough nanoscale platforms for molecular diagnostics, personalized medicine and biomedical research, today announced the appointment of Gary Zweiger, Ph.D., as vice president of business development. Dr. Zweiger has over...

Designing Our Descendants.
In one of the classic early discussions about the possible uses of advancing genetic knowledge to control and reshape human life, Paul Ramsey, more than thirty years ago, wrote the following: I ... raise the question whether a scientist has not an entirely "frivolous conscience" who, faced...

It takes three.
NOT SO LONG AGO MAKING A BABY WAS SIMPLY ABOUT THE BIRDS AND the bees. Then technological advances brought a host of new aids. The latest, cytoplasmic transfer, offers an infertile woman one last chance to have a baby genetically her own. Since its introduction in 1996, some 30...

New Report Cites Emerging Impact of Personalized Medicine on Healthcare.
-- Report from Personalized Medicine Coalition Issued at the 2nd Annual Burrill Personalized Medicine Meeting -- SAN FRANCISCO, Nov. 14 /PRNewswire/ -- "The Case for Personalized Medicine," a comprehensive review assessing the state of personalized medicine and the evidence that it will become an integral part of...

Sequenom and QIAGEN Enter Into Collaboration Targeting Prenatal Diagnostics.
SAN DIEGO and VENLO, Netherlands, Jan. 8 /PRNewswire-FirstCall/ -- Sequenom, Inc. and QIAGEN GmbH, a wholly-owned subsidiary of QIAGEN N.V. (Nasdaq: QGEN; Frankfurt, Prime Standard: QIA), today announced that they have entered into a strategic collaboration to jointly develop a gold-standard preanalytical solution for small molecule (fetal) DNA enrichment...

Sequenom and Lenetix Enter Agreement to Develop and Commercialize Rhesus D Prenatal Diagnostic.
Sequenom's First Non-Invasive Prenatal Diagnostic Test On Track to Launch in First Half of 2007 SAN DIEGO and MINEOLA, N.Y., Jan. 29 /PRNewswire-FirstCall/ -- Sequenom, Inc. and Lenetix Medical Screening Laboratory, Inc., a provider of rapid genetic screening and diagnostic testing for clinicians worldwide, today announced that...

Sequenom and Genus Enter Into Large Scale Livestock Genotyping Services Contract.
SAN DIEGO, Jan. 17 /PRNewswire-FirstCall/ -- Sequenom, Inc. today announced that it will provide contract genotyping services to Genus plc , a world leader in applying quantitative genetics and biotechnology to livestock breeding, for a number of large-scale, high-throughput genotyping projects aimed at accelerating Genus' livestock research and development...

Sequenom Names Steven Owings Vice President of Commercial Development, Prenatal Diagnostics.
SAN DIEGO, Feb. 5 /PRNewswire-FirstCall/ -- Sequenom, Inc. today announced that it has named Steven Owings to the newly created position of Vice-President of Commercial Development, Prenatal Diagnostics. Mr. Owings will lead the Company's commercialization of its non-invasive prenatal diagnostic technology currently under development. The Company expects application of...

Shaping priorities in genetic medicine.
Genetic technology, touted as one of the great revolutions of medicine--and as salvation for many who suffer from intractable disease--is well on its way to a clinic near you. Thanks to rapid private-sector advances in molecular biology and a $3 billion federal Human Genome Project that will map and sequence...

Regulating nutrigenetic tests: an international comparative analysis.
Introduction In September 2007, the decoded genome of J. Craig Venter, a pioneering genetics researcher, was released to the world. (1) This achievement attracted worldwide media attention, with stories making the inevitable leap from the publication of one man's genome to the promise of personalized medicine for...